Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices

Inward Investment
Return to: PBR Home | Inward Investment

Inward Investment

Merck in talks to acquire Cubist Pharmaceuticals for nearly $8bn By PBR Staff Writer
New Jersey-based drug giant Merck & Co is, reportedly, in talks over a potential acquisition of antibiotics maker Cubist Pharmaceuticals for more than $8bn.
Inward Investment > News
Endo International to buy Auxilium Pharmaceuticals for $2.6bn By PBR Staff Writer
Ireland-based Endo International has signed an agreement to acquire Auxilium Pharmaceuticals, in a deal that is worth nearly $2.6bn.
Inward Investment > News Endo offers $2.2bn to acquire Auxilium By PBR Staff Writer
Irish pain drugmaker Endo International has proposed $2.2bn offer to acquire biopharmaceutical company Auxilium Pharmaceuticals.
Inward Investment > News
See more Inward Investment news

Latest Inward Investment News and Insight

View all Inward Investment news or find news targeted to your interests
Cognizant agrees to buy TriZetto for $2.7bn
By PBR Staff Writer
Cognizant has signed a definitive agreement to acquire US-based healthcare IT software and solutions provider TriZetto for $2.7bn in cash.
Inward Investment > News
Janssen's Cilag International acquires biopharmaceutical firm Covagen
By PBR Staff Writer
Janssen Pharmaceutical's affiliate Cilag International has completed the acquisition of Covagen, Swiss biopharmaceutical firm specializing in the development of multispecific protein therapeutics through its FynomAb technology platform.
Inward Investment > News
Recipharm to buy Corvette Pharmaceutical Services for $160m
By PBR Staff Writer
Swedish contract development and manufacturing organisation Recipharm has agreed to purchase Milan based Corvette Pharmaceutical Services Group (Corvette) from Italian private equity group LBO Italia Investimenti.
Inward Investment > News
Novartis agrees to acquire 15% stake in Gamida Cell
By PBR Staff Writer
Swiss drugmaker Novartis Pharma has signed an agreement to acquire 15% stake in Gamida Cell for $35m.
Inward Investment > News
Amgen to buy Onyx Pharmaceuticals for $10.4bn
By PBR Staff Writer
Biotechnology company Amgen has reached a deal to buy all outstanding shares of California-based Onyx Pharmaceuticals for $125 per share in cash.
Inward Investment > News
Johnson & Johnson completes purchase of Aragon Pharmaceuticals
By PBR Staff Writer
Johnson & Johnson has completed the acquisition of Aragon Pharmaceuticals, a pharmaceutical discovery and development company focused on drugs to hormonally-driven cancers.
Inward Investment > News
Breckenridge to acquire certain assets of Cypress Pharmaceuticals
By PBR Staff Writer
Pharmaceutical marketing, research and development company Breckenridge Pharmaceutical has signed a deal to acquire certain assets of Pernix Therapeutics' subsidiary, Cypress Pharmaceuticals, for $30m.
Inward Investment > News
Actavis takes over Palau Pharma's Albaconazole antifungal agent
By PBR Staff Writer
Actavis Specialty Brands has purchased worldwide rights for Palau Pharma's Albaconazole antifungal agent indicated for the treatment of vulvo-vaginal candidiasis, onychomycosis and other antifungal applications.
Inward Investment > News
Cubist to acquire Optimer Pharmaceuticals and Trius Therapeutics
By PBR Staff Writer
Cubist Pharmaceuticals has entered into two separate agreements to acquire Optimer Pharmaceuticals and Trius Therapeutics, as part of the company's Building Blocks of Growth strategy to strengthen its presence in acute care and hospital environments.
Inward Investment > News
Pfizer plans internal classification of commercial businesses
By PBR Staff Writer
Pfizer is planning for internal classification of its commercial operations into three business segments, which will include developed and emerging markets, in an effort to deliver value to consumers and patients.
Inward Investment > News
View all Inward Investment news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250